Back to Results

Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for age-related degenerative diseases, with an emphasis on disorders of the central nervous system and the retina. The company’s lead candidate is CT1812, an orally administered molecule modulator designed to cross the blood-brain barrier and selectively bind to the S2R complex. CT1812 is being evaluated in Phase 2 studies for Alzheimer’s disease, geographic atrophy associated with dry age-related macular degeneration, and synucleinopathies, including dementia with Lewy bodies. Cognition Therapeutics was incorporated in 2007 and is headquartered in Purchase, New York. Its common stock trades on the NASDAQ under the symbol CGTX.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CGTX
$0.61
-3.2% Downside
Fair
$3.33
424.9% Upside
Bargain
Fair
0.0%
1.8x
60.423 M
26.962 M
1.0%
92.0%
-3.4
105.5%
Valuation • Fair Value

Cognition Therapeutics Inc (NASDAQ-CGTX) Fair Value by Valuation Model

Review the available estimates for Cognition Therapeutics Inc (NASDAQ-CGTX), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.61

Estimated downside of 3.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.42

Discounted cash flow valuation reference.

Comps Fair Value

$0.75

Comparable-company valuation reference.

Analyst Price Target

$3.33

Analysts imply upside of 424.9%.

How to read these valuation models

Use the 5 available valuation references for Cognition Therapeutics Inc (NASDAQ-CGTX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cognition Therapeutics Inc (NASDAQ-CGTX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-36.551 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Cognition Therapeutics Inc (NASDAQ-CGTX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cognition Therapeutics Inc (NASDAQ-CGTX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-3.4

Lower score that deserves closer risk review.

FCF / Net Income

105.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cognition Therapeutics Inc (NASDAQ-CGTX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Cognition Therapeutics Inc (NASDAQ-CGTX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Cognition Therapeutics Inc (NASDAQ-CGTX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Cognition Therapeutics Inc (NASDAQ-CGTX) Stock Forecast & Technical Outlook

Review Cognition Therapeutics Inc (NASDAQ-CGTX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cognition Therapeutics Inc (NASDAQ-CGTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cognition Therapeutics Inc (NASDAQ-CGTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Cognition Therapeutics Inc (NASDAQ-CGTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Cognition Therapeutics Inc (NASDAQ-CGTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Cognition Therapeutics Inc (NASDAQ-CGTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cognition Therapeutics Inc (NASDAQ-CGTX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Cognition Therapeutics Inc (NASDAQ-CGTX) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Cognition Therapeutics Inc (NASDAQ-CGTX) Stock FAQ

Data-supported answers about Cognition Therapeutics Inc (NASDAQ-CGTX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.61
Estimated downside 3.2%
Valuation Rating
Overvalued
Estimated downside of 3.2%
Analyst Target
$3.33
Implied upside 424.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Cognition Therapeutics Inc (NASDAQ-CGTX) is $0.61. This implies an estimated downside of 3.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 3.2% versus the current market price.

The available analyst price target for Cognition Therapeutics Inc (NASDAQ-CGTX) is $3.33. The analyst target implies estimated upside of 424.9%.

The current financial health read for Cognition Therapeutics Inc (NASDAQ-CGTX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Cognition Therapeutics Inc (NASDAQ-CGTX).

The current market capitalization listed for Cognition Therapeutics Inc is 60.423 M.

The current enterprise value listed for Cognition Therapeutics Inc is 26.962 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cognition Therapeutics Inc is NASDAQ-CGTX, and the stock is listed on NASDAQ.

Cognition Therapeutics Inc (NASDAQ-CGTX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cognition Therapeutics Inc is 1.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cognition Therapeutics Inc is 92.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B